drugset / Trial / NCT06176508

Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

NCT06176508

Phase 2 Recruiting 160 enrolled Hansoh BioMedical R&D Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of active psoriatic arthritis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.

Timeline

Start
2024-02-26
Primary completion
2026-04-28
Completion
2026-08-28

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-10374 Unknown Oral
Comparator Tofacitinib Small molecule 5 mg Oral

Indications